Diagnostic Kits. Early detection of invasion and spreading of
malignant tumors.
Overview
Established in September 2002, InCure Ltd. is a start-up
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
biotechnology company developing a detection immunological kit of
solid carcinoma invasion and metastasis in blood samples.
InCure's mission is to establish itself as a leader in the field
of gene therapy developing innovative diagnostic and therapeutic
products for the treatment of oncolytic diseases by capitalizing
on the numerous clinical applications offered by its proprietary
technology.
Detection of potential tumor invasion is critical for determining
the appropriate treatment strategies and improving recovery
prospects. A critical event in malignant tumor development is the
acquisition of the ability to invade through basement membranes
and then reemerge from the blood vessels to establish new
metastatic colonies at distant sites. The PAR1 (Proteolytically
Activated Receptor-1) ligand is preferentially over expressed in
highly metastatic biopsy specimens and is found to play a central
role in the malignant and physiological invasion processes in
several cancers. Abrogation and neutralization of the PAR1 gene
expression (the PAR1 antisense) markedly inhibits the invasive
potential of cells, and suggests a therapeutic means targeted to
inhibit the PAR1 ligand. InCure is currently focusing on
developing a gene diagnostic test for breast and colon cancer.
